A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Researchers have traced the earliest stages of multiple sclerosis (MS), showing that the immune system begins attacking the brain up to seven years before diagnosis.

LONDON — Previous research has shown that providing a clinically definite multiple sclerosis (MS) diagnosis often takes several weeks or even months. But new research suggests that a new "technology ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases ...

The Valhalla Foundation awarded Octave Bioscience funding to further develop a biomarker blood test for assessing disease ...

Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative diseases, today announced that it is ...